Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: Enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques

Journal of Leukocyte Biology

Volumn 80, Issue 5, 2006, Pages 1175-1182

  Kennedy, Paul E ^a   Bera, Tapan K ^b   Wang, Qing Cheng ^b   Gallo, Maria ^b   Wagner, Wendeline ^c   Lewis, Mark G ^c   Berger, Edward A ^a   Pastan, Ira ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

HAART; Reservoirs persistence; Targeted killing

Indexed keywords

CHIMERIC PROTEIN; GAG PROTEIN; GLYCOPROTEIN GP 120; IMMUNOTOXIN; IMMUNOTOXIN 3B3(FV) PE38; IMMUNOTOXIN CD4(178) PE40; MEMBRANE PROTEIN; PSEUDOMONAS EXOTOXIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ARTICLE; CELL ISOLATION; CELL KILLING; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MACACA; MACROPHAGE; MORBIDITY; MORTALITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; TARGET CELL; VIRUS ISOLATION; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXOTOXINS; HIV; HUMANS; IMMUNOTOXINS; INJECTIONS, INTRAVENOUS; LEUKOCYTES, MONONUCLEAR; LIVER DISEASES; MACACA; MACROPHAGES; MODELS, ANIMAL; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA MULATTA; PSEUDOMONAS AERUGINOSA;

EID: 33750427894     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0306139     Document Type: Article

References (61)

1. Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S., Schooley, R. T., Jacobsen, D. M., Thompson, M. A., Carpenter, C. C., Fischl, M. A., Gazzard, B. G., Gatell, J. M., Hirsch, M. S., Katzenstein, D. A., Richman, D. D., Vella, S., Yeni, P. G., Volberding, P. A. (2006) Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296, 827-843.
2. Lassen, K., Han, Y. F., Zhou, Y., Siliciano, J., Siliciano, R. F. (2004) The multifactorial nature of HIV-1 latency. Trends Mol. Med. 10, 525-531.
3. Shehu-Xhilaga, M., Tachedjian, G., Crowe, S. M., Kedzierska, K. (2005) Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1. Curr. Med. Chem. 12, 1705-1719.
4. Greene, W. (2004) The brightening future of HIV therapeutics. Nat. Immunol. 5, 867-871.
5. Kelly, L. M., Lisziewicz, J., Lori, F. (2004) "Virostatics" as a potential new class of HIV drugs. Curr. Pharm. Des. 10, 4103-4120.
6. Chun, T.-W., Fauci, A. S. (1999) Latent reservoirs of HIV: obstacles to the eradication of virus. Proc. Natl. Acad. Sci. USA 96, 10958-10961.
7. Hezareh, M. (2005) Prostratin as a new therapeutic agent targeting HIV viral reservoirs. Drug News Perspect. 18, 496-500.
8. Demonte, D., Quivy, V., Colette, Y., Van Lint, C. (2004) Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies. Biochem. Pharmacol. 68, 1231-1238.
9. Nunnari, G., Pomerantz, R. J. (2005) Il-7 as a potential therapy for HIV-1-infected individuals. Expert Opin. Biol. Ther. 5, 1421-1426.
10. Chun, T.-W., Engel, D., Mizell, S. B., Hallahan, C. W., Fischette, M., Park, S., Davey, R. T., Dybul, M., Kovacs, J. A., Metcalf, J. A., et al. (1999) Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active antiretroviral therapy. Nat. Med. 5, 651-655.
11. Lafeuillade, A., Poggi, C., Chadapaud, S., Hittinger, G., Chouraqui, M., Pisapia, M., Delbeke, E. (2001) Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission. J. Acq. Immun. Def. Syn. 26, 44-55.
12. Kulkosky, J., Nunnari, G., Otero, M., Calarota, S., Dornadula, G., Zhang, H., Malin, A., Sullivan, J., Xu, Y., DeSimone, J., et al. (2002) Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J. Infect. Dis. 186, 1403-1411.
13. Lehrman, G., Hogue, I. B., Palmer, S., Jennings, C., Spina, C. A., Wiegand, A., Landay, A. L., Coombs, R. W., Richman, D. D., Mellors, J. W., et al. (2005) Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366, 549-555.
14. Kinloch-de Loes, S., Autran, B. (2002) HIV-1 therapeutic vaccines. J. Infect. 44, 152-159.
15. Gilliam, B. L., Redfield, R. R. (2003) Therapeutic HIV vaccines. Curr. Top. Med. Chem. 3, 1536-1553.
16. Puls, R. L., Emery, S. (2006) Therapeutic vaccination against HIV: current progress and future possibilities. Clin. Sci. 110, 59-71.
17. Kinloch-de Loes, S., Hoen, B., Smith, D. E., Autran, B., Lampe, F. C., Phillips, A. N., Goh, L. E., Andersson, J., Tsoukas, C., Sonnerborg, A., et al. (2005) Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J. Infect. Dis. 192, 607-617.
18. Engert. A., Sausville, E. A., Vitetta, E. (1998) The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma. Curr. Top. Microbiol. Immunol. 234, 13-33.
19. Frankel, A. E., Neville, D. M., Bugge, T. A., Kreitman, R. J., Leppla, S. H. (2003) Immunotoxin therapy of hematologic malignancies. Semin. Oncol. 30, 545-557.
20. Pastan, I., Hassan, R., Fitzgerald, D. J., Kreitman, R. J. (2006) Immunotoxin therapy of cancer. Nat. Rev. Cancer 6, 559-565.
21. Berger, E. A., Moss, B., Pastan, I. (1998) Reconsidering targeted toxins to eliminate HIV infection: You gotta have HAART. Proc. Natl. Acad. Sci. USA 95, 11511-11513.
22. Van Oijen, M. G. C. T., Preijers, F. W. M. B. (1998) Rationale for the use of immunotoxins in the treatment of HIV-infected humans. J. Drug Target 5, 75-91.
23. Chaudhary, V. K., Mizukami, T., Fuerst, T. R., FitzGerald, D. J., Moss, B., Pastan, I., Berger, E. A. (1988) Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature 335, 369-372.
24. Ramachandran, R. V., Katzenstein, D. A., Wood, R., Batts, D. H., Merigan, T. C. (1994) Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons. J. Infect. Dis. 170, 1009-1013.
25. Davey, R. T., Boenning, C. M., Herpin, B. R., Batts, D. H., Metcalf, J. A., Wathen, L., Cox, S. R., Polis, M. A., Kovacs, J. A., Falloon, J., et al. (1994) Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus. J. Infect. Dis. 170, 1180-1188.
26. Bera, T. K., Kennedy, P. E., Berger, E. A., Barbas, C. F. I., Pastan, I. (1998) Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein. Mol. Med. 4, 384-391.
27. Barbas, C. F., Hu, D., Dunlop, N., Sawyer, L., Cababa, D., Hendry, R. M., Nara, P. L., Burton, D. R. (1994) In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc. Natl. Acad. Sci. USA 91, 3809-3813.
28. Chowdhury, P. S., Viner, J. L., Beers, R., Pastan, I. (1998) Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc. Natl. Acad. Sci. USA 95, 669-674.
29. Lazdins, J. K., Woods-Cook, K., Walker, M., Alteri, E. (1990) The lipophilic muramyl peptide MTP-PE is a potent inhibitor of HIV replication in macrophages. AIDS Res. Hum. Retroviruses 6, 1157-1161.
30. Berger, E. A., Clouse, K. A., Chaudhary, V. K., Chakrabarti, S., FitzGerald, D. J., Pastan, I., Moss, B. (1989) CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses. Proc. Natl. Acad. Sci. USA 86, 9539-9543.
31. Ashorn, P., Englund, G., Martin, M. A., Moss, B., Berger, E. A. (1991) Anti-HIV activity of CD4-Pseudomonas exotoxin on infected primary human lymphocytes and monocyte/macrophages. J. Infect. Dis. 163, 703-709.
32. Ashorn, P., Moss, B., Berger, E. A. (1992) Activity of CD4-Pseudomonas exotoxin against cells expressing diverse forms of the HIV and SIV envelope glycoproteins. J. Acq. Immun. Def. Syn. 5, 70-77.
33. Kennedy, P. E., Moss, B., Berger, E. A. (1993) Primary HIV-1 isolates refractory to neutralization by soluble CD4 are potently inhibited by CD4-Pseudomonas exotoxin. Virology 192, 375-379.
34. Daar, E. S., Li, X. L., Moudgil, T., Ho, D. D. (1990) High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci. USA 87, 6574-6578.
35. Crowe, S., Zhu, T. F., Muller, W. A. (2003) The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection. J. Leukoc. Biol. 74, 635-641.
36. Verani, A., Gras, G., Pancino, G. (2005) Macrophages and HIV-1: dangerous liaisons. Mol. Immunol. 42, 195-212.
37. LeMaistre, C. F., Saleh, M. N., Kuzel, T. M., Foss, F., Platanias, L. C., Schwartz, G., Ratain, M., Rook, A., Freytes, C. O., Craig, F., et al. (1998) Phase I trial of a ligand fusion-protein (dab(389)IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 91, 399-405.
38. Kreitman, R. J., Wilson, W. H., Robbins, D., Margulies, I., Stetler-Stevenson, M., Waldmann, T. A., Pastan, I. (1999) Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 94, 3340-3348.
39. Kreitman, R. J., Wilson, W. H., White, J. D., Stetler-Stevenson, M., Jaffe, E. S., Giardina, S., Waldmann, T. A., Pastan, I. (2000) Phase I trial of recombinant immunotoxin anti-Tac(Fv)PE38 (LMB- 2) in patients with hematologic malignancies. J. Clin. Oncol. 18, 1622-1636.
40. Kreitman, R. J., Wilson, W. H., Bergeron, K., Raggio, M., Stetler-Stevenson, M., FitzGerald, D. J., Pastan, I. (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL-22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 345, 241-247.
41. Kreitman, R. J., Squires, D. R., Stetler-Stevenson, M., Noel, P., Fitzgerald, D. J. P., Wilson, W. H., Pastan, I. (2005) Phase 1 trial of recombinant immunotoxin rfb4(dsFv)-PE38 (BL-22) in patients with B-cell malignancies. J. Clin. Oncol. 23, 6719-6729.
42. Bross, P. F., Beitz, J., Chen, G., Chen, X. H., Duffy, E., Kieffer, L., Roy, S., Sridhara, R., Rahman, A., Williams, G., et al. (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7, 1490-1496.
43. Till, M. A., Ghetie, V., Gregory, T., Patzer, E. J., Porter, J. P., Uhr, J. W., Capon, D. J., Vitetta, E. S. (1988) HIV-infected cells are killed by rCD4-ricin A chain. Science 242, 1166-1168.
44. Pincus, S. H., Wehrly, K., Chesebro, B. (1989) Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates. J. Immunol. 142, 3070-3075.
45. Aullo, P., Alcami, J., Popoff, M. R., Klatzmann, D. R., Murphy, J. R., Boquet, P. (1992) A recombinant diphtheria toxin related human CD4 fusion protein specifically kills HIV infected cells which express gp120 but selects fusion toxin resistant cells which carry HIV. EMBO J. 11, 575-583.
46. Erice, A., Balfour, H. H., Myers, D. E., Leske, V. L., Sannerud, K. J., Kuebelbeck, V., Irvin, J. D., Uckun, F. M. (1993) Anti-human immunodeficiency virus type-1 activity of an anti-CD4 immunoconjugate containing pokeweed antiviral protein. Antimicrob. Agents Chemother. 37, 835-838.
47. Al-jaufy, A. Y., Haddad, J. E., King, S. R., Mcphee, R. A., Jackson, M. P. (1994) Cytotoxicity of a Shiga toxin a subunit-CD4 fusion protein to human immunodeficiency virus-infected cells. Infect. Immun. 62, 956-960.
48. Sidorov, A. V., Zdanovsky, A. G., Zverev, V. V., Pugach, A. V., Malyushova, V. V., Anjaparidze, O. G. (1994) Antiviral properties of the recombinant receptorotoxins consisting of diphtheria toxin and CD4-receptor fragments. Vopr. Virusol. 39, 6-10.
49. Mori, T., Shoemaker, R. H., McMahon, J. B., Gulakowski, R. J., Gustafson, K. R., Boyd, M. R. (1997) Construction and enhanced cytotoxicity of a [cyanovirin-N]- [Pseudomonas exotoxin] conjugate against human immunodeficiency virus-infected cells. Biochem. Biophys. Res. Commun. 239, 884-888.
50. Martin-Serrano, J., Folgueira, L., de Lera, T. L., Pedraza, M. A., Lemichez, E., Sanchez-Palomino, S., Noriega, A. R., Boquet, P., Alcami, J. (1998) In vitro selective elimination of HIV-infected cells from peripheral blood in AIDS patients by the immunotoxin DAB389CD4. AIDS 12, 859-863.
51. Finberg, R. W., Wahl, S. M., Allen, J. B., Soman, G., Strom, T. B., Murphy, J. R., Nichols, J. C. (1991) Selective elimination of HIV-1-infected cells with an interleukin-2 receptor-specific cytotoxin. Science 252, 1703-1705.
52. Zhang, L., Waters, C., Nichols, J., Crumpacker, C. (1992) Inhibition of HIV-1 RNA Production by the Diphtheria Toxin- Related IL-2 Fusion Proteins DAB(486)IL-2 and DAB(389)IL-2. J. Acq. Immun. Defic. Syndrome. 5, 1181-1187.
53. Bell, K. D., Ramilo, O., Vitetta, E. S. (1993) Combined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T-cells from producing type-1 human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 90, 1411-1415.
54. McCoig, C., Van Dyke, G., Chou, C. S., Picker, L. J., Ramilo, O., Vitetta, E. S. (1999) An anti-CD45RO immunotoxin eliminates T cells latently infected with HIV-1 in vitro. Proc. Natl. Acad. Sci. USA 96, 11482-11485.
55. Saavedra-Lozano, J., McCoig, C., Xu, J. B., Cao, Y. Y., Keiser, P., Ghetie, V., Siliciano, R. F., Siliciano, J. D., Picker, L. J., Ramilo, O., et al. (2002) An anti-CD45RO immunotoxin kills latently infected human immunodeficiency virus (HIV) CD4 T cells in the blood of HIV-positive persons. J. Infect. Dis. 185, 306-314.
56. Saavedra-Lozano, J., Cao, Y., Callison, J., Sarode, R., Sodora, D., Edgar, J., Hatfield, J., Picker, L., Peterson, D., Ramilo, O., et al. (2004) An anti-CD45RO immunotoxin kills HIV-latently infected cells from individuals on HAART with little effect on CD8 memory. Proc. Natl. Acad. Sci. USA 101, 2494-2499.
57. Bruhl, H., Cihak, J., Stangassinger, M., Schlondorff, D., Mack, M. (2001) Depletion of CCR5-expressing cells with bispecific antibodies and chemokine toxins: a new strategy in the treatment of chronic inflammatory diseases and HIV. J. Immunol. 166, 2420-2426.
58. Onda, M., Kreitman, R. J., Vasmatzis, G., Lee, B., Pastan, I. (1999) Reduction of the nonspecific animal toxicity of anti-Tac(Fv)- PE38 by mutations in the framework regions of the Fv which lower the isoelectric point. J. Immunol. 163, 6072-6077.
59. Onda, M., Nagata, S., Tsutsumi, Y., Vincent, J. J., Wang, Q. C., Kreitman, R. J., Lee, B., Pastan, I. (2001) Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. Cancer Res. 61, 5070-5077.
60. Ashorn, P., Moss, B., Weinstein, J. N., Chaudhary, V. K., FitzGerald, D. J., Pastan, I., Berger, E. A. (1990) Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors. Proc. Natl. Acad. Sci. USA 87, 8889-8893.
61. Goldstein, H., Pettoello-Mantovani, M., Bera, T. K., Pastan, I. H., Berger, E. A. (2000) Chimeric toxins targeted to the human immunodeficiency virus type 1 envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy/liv-SCID-hu mice. J. Infect. Dis. 181, 921-926.